Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Elanco makes and sells medicines, vaccines, and other health products for pets and farm animals around the world.
Elanco is a drug company for animals. If your dog has an ear infection, fleas, or arthritis, or if a farmer's chickens and pigs need protection from disease, Elanco sells the medicine and vaccines that keep those animals healthy. It serves two broad groups: pet owners and veterinarians on one side, and livestock producers on the other.
The pet side is where the growth story lives. People are spending more on their dogs and cats than ever, and they increasingly treat pet health like human health, paying for premium food, preventive care, and drugs. Elanco sells flea and tick treatments, dewormers, and medicines for pain and skin conditions. The farm side is steadier but tougher: Elanco sells vaccines and antibiotics for poultry, swine, cattle, and fish, and farmers buy these to keep herds productive. That business rises and falls with meat prices and farm economics, and it carries the company's heaviest load of public criticism — concerns about antibiotic use in livestock and the push to reduce it. Elanco is not the biggest player. It competes hard against Zoetis, the industry leader, and Merck, which runs a large animal health division, plus a crowd of smaller rivals. Elanco's edge comes from its portfolio of well-known brands, its global sales reach, and the fact that once a vet or farmer trusts a product, switching is a hassle. Still, it spent years digesting a huge acquisition — buying Bayer's animal health business in 2020 for around $7 billion — which added debt and complexity and took management's focus. Earnings have been lumpy since, and the company has been working to cut costs and pay that debt down.
The company is based in Greenfield, Indiana, a nod to its Midwestern farming roots: it was spun out of Eli Lilly, the human drugmaker, in 2018. Its bet today is simple — that people will keep spending on their pets, and that it can win back momentum in a market where the leader keeps pulling ahead. Whether that bet pays off depends on new products landing well and on the debt load shrinking faster than the competition grows.
Saved answer · last researched 15 Nov 2026